Stay updated with breaking news from Cassava Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
An Independent Data and Safety Monitoring Board Recently Evaluated the Interim Patient Safety Database for Simufilam in On-Going Phase 3 Clinical Trials.The DSMB Recommended the Phase 3 Trials of...
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Simufilam in On-Going Phase 3 Clinical...
On CNBC’s "Mad Money Lightning Round," Jim Cramer said ONEOK, Inc's (NYSE: OKE) management is terrific. "The CFO Walter Hulse is like you and me, a Jersey-ite.
New cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease.Results corroborate prior research from...
AUSTIN, Texas, Sept. 06, 2023 -- Cassava Sciences, Inc. , a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that it has been invited to present...